Newsfeeds - Spark Newswire

4 minute read

News

Vistagen Announces Results Of Voting From 2022 Annual Meeting Of Stockholders And Partial Adjournment To October 28, 2022

October 19, 4:45 PM

Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common

VTGN

47 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

October 11, 12:47 PM

On Tuesday, 838 companies hit new 52-week lows.

$APE

4 minute read

Vistagen Announces The Two Leading Proxy Advisory Firms, Institutional Shareholder Services And Glass Lewis, Recommend Stockholders Vote “For” Proposal No. 5 To Provide Its Board With The Option To Implement A Future Reverse Stock Split, If Necessary

By Benzinga Newsdesk

October 6, 8:39 AM

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central

VTGN

2 minute read

Why Zumiez Is Trading Lower By 14%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

September 9, 6:35 AM

Gainers Infobird Co., Ltd (NASDAQ: IFBD) rose 70.8% to $3.16 in pre-market trading after 1:5 reverse stock split takes effect.

AYLA

6 minute read

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday

By Lisa Levin

September 9, 4:13 AM

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.

AEO

4 minute read

Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

September 8, 6:17 PM

The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…

ALNY

1 minute read

Independent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial

By Vandana Singh

September 8, 2:24 PM

Vistagen Therapeutics Inc (NASDAQ:VTGN) completed an interim analysis of PALISADE-2, its second Phase 3 trial assessing drug candidate PH94B as an…

VTGN

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

August 22, 5:38 PM

Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million.

ABVC